abstract |
The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5- isopropyl-4H- 1,2,4-triazol-4-yl)piperidin- 1 -yl]butyl} - 1 -(methylsulfonyl)piperidine formula (I) : or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states. |